{"id":2363,"date":"2020-09-09T16:47:06","date_gmt":"2020-09-09T16:47:06","guid":{"rendered":"http:\/\/www.ijmhr.org\/IntJAnatRes\/?page_id=2363"},"modified":"2020-09-09T16:47:06","modified_gmt":"2020-09-09T16:47:06","slug":"ijar-2020-204","status":"publish","type":"page","link":"https:\/\/www.ijmhr.org\/IntJAnatRes\/ijar-2020-204","title":{"rendered":"IJAR.2020.204"},"content":{"rendered":"
<\/i> DOWNLOAD PDF<\/span><\/a><\/div><\/div><\/div>
<\/i> Table of Contents<\/span><\/a><\/div><\/div><\/div><\/div>\n

Type of Article:<\/strong>\u00a0\u00a0Original Research<\/h3>\n

Volume 8; Issue 3.3 (September 2020)<\/strong><\/h3>\n

Page No.:<\/strong>\u00a07728-7737<\/h3>\n

DOI:\u00a0<\/strong>https:\/\/dx.doi.org\/10.16965\/ijar.2020.204<\/h3>\n

PROMISING EFFECT OF DAPAGLIFLOZIN ON OVARIECTOMIZED RAT MODEL OF OSTEOPOROSIS<\/h3>\n

Amany Ali Nawar 1<\/sup>, Nancy Mohamed El Sekily *2<\/sup>.<\/strong><\/p>\n

1<\/sup> Clinical pharmacology Department, Faculty of Medicine, Alexandria University, Egypt.<\/p>\n

*2<\/sup> Anatomy and Embryology Department, Faculty of Medicine, Alexandria University, Egypt.<\/p>\n

Corresponding author: <\/strong>Nancy Mohamed Aly El-Sekily, Anatomy and Embryology, Department, Faculty of Medicine, Alexandria University, Egypt. +0201222359100\u00a0E-Mail:<\/strong> nancyelsekily@yahoo.com<\/p>\n

ABSTRACT<\/h3>\n

Introduction: <\/strong>Osteoporosis makes bones become frail thus fragile, that a fall or even gentle burdens prompting a crack. Several studies had documented that osteoporosis incidence is increased much more in diabetic patient. Dapagliflozin, is used in Type 2 diabetes management, as a selective inhibitor of sodium\/glucose cotransporter-2 (SGLT2). Few study tackled the impact of dapagliflozin on bone metabolism. In this study we aim to determine the impact of dapagliflozin on a rat model of osteoporosis.<\/p>\n

Materials and methods<\/strong>: Thirty adult female Wistar albino rats were used in this experiment. They were equally divided into three groups. Group I<\/em> sham-operated control, group II ovariectomized (OVX), and group III ovariectomized (OVX) treated with dapagliflozin (DAPA) 10 mg\/kg\/day orally for 8 weeks. After 8weeks, plasma levels of calcium (Ca+2), phosphorous (P), alkaline phosphatase (ALP), Tartrate-Resistant Acid Phosphatase 5b (TRAP 5b), tumor necrosis factor-\u03b1 (TNF-\u03b1), serum osteocalcin level, serum osteoprotegerin level, AMP-activated protein kinase (AMPK) and advanced glycosylation end products (AGEs) were analysed. The distal end of femur bones were excised for histological and morphometric studies.<\/p>\n

Results<\/strong>: In the current study, the biochemical results of ovariectomized (OVX) rat group showed increase in serum level of phosphorus, alkaline phosphatase, Tartrate-Resistant Acid Phosphatase 5b (TRAP 5b), osteocalcin, advanced glycosylation end products (AGEs) and tumor necrosis factor-\u03b1 (TNF-\u03b1) . While the serum level of calcium, osteoprotegrin and AMP-activated protein kinase (AMPK) was decreased. The biochemical results of (OVX) group treated with DAPA showed a significant change in serum level of calcium, alkaline phosphatase, TRAP 5b, osteocalcin, osteoprotegrin and AMPK. While the serum level of phosphorus, AGEs and TNF- \u03b1 showed non significant change in the same group. In the present study, the (OVX) rat group showed features of osteoporosis at the epiphyseal plate of femur. These features were focal areas of disrupted arrangement of the layers of chondrocytes, some areas of the matrix appeared pale, the bone trabeculae were thinner than normal, multiple resorption cavities and some areas of hypocellularity. After oral administration of dapagliflozin to the OVX rats for eight weeks, the osteoporotic findings in femur by H&E showed improvement. The chondrocytes appeared almost normally organized and the bone trabeculae were of normal thickness. By morphometric assessment, the thickness of bone trabeculae of OVX treated with DAPA group (69.9\u00b115.6) increased in comparaison to the OVX group (61.0\u00b1 18.2).<\/p>\n

Conclusion<\/strong>: Dapaglaflozin has an antiosteoporotic effect in ovariectomy induced osteoporosis in rat.<\/p>\n

KEY WORDS: <\/strong>Dapagliflozin, Osteoporosis, bilateral ovaricteomy.<\/p>\n

REFERENCES<\/strong><\/p>\n

[1]. Shuid AN, Ping LL, Muhammad N, Mohamed N, Soelaiman IN. The effects of Labisia pumila var.alata on bone markers and bone calcium in a rat model of post-menopausal osteoporosis. J Ethnopharmacol 2011;133(2):538-542.
\nhttps:\/\/doi.org\/10.1016\/j.jep.2010.10.033
\nPMid:20971181
\n[2]. Sambrook PN, Eisman JA. Osteoporosis prevention and treatment. Med J Aust. 2000;172(5):226-9.
\nhttps:\/\/doi.org\/10.5694\/j.1326-5377.2000.tb123917.x
\nPMid:10776395
\n[3]. Russo GT, Giandalia A, Romeo EL, Nunziata M, Muscianisi M, Ruffo MC, Catalano A, Cucinotta D. Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences. Int J Endocrinol. 2016;1615735.
\nhttps:\/\/doi.org\/10.1155\/2016\/1615735
\nPMid:28044077 PMCid:PMC5164892
\n[4]. Yang DH, Chiang TI, Chang IC, Lin FH, Wei CC, Cheng YW. Increased levels of circulating advanced glycation end-products in menopausal women with osteoporosis. Int J Med Sci. 2014;11(5):453-60.
\nhttps:\/\/doi.org\/10.7150\/ijms.8172
\nPMid:24688308 PMCid:PMC3970097
\n[5]. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93(4):1143-52.
\nhttps:\/\/doi.org\/10.1210\/jc.2007-1817
\nPMid:18182449
\n[6]. Masahiro Yamamoto1 & Toshitsugu Sugimoto. Advanced Glycation End Products, Diabetes, and Bone Strength. Curr Osteoporos Rep. 2016;14:320-326.
\nhttps:\/\/doi.org\/10.1007\/s11914-016-0332-1
\nPMid:27704396 PMCid:PMC5104767
\n[7]. AlikhaniM, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone. 2007;40(2):345-53.
\nhttps:\/\/doi.org\/10.1016\/j.bone.2006.09.011
\nPMid:17064973 PMCid:PMC1913208
\n[8]. Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res. 2007;39(12):871-5.
\nhttps:\/\/doi.org\/10.1055\/s-2007-991157
\nPMid:17960513
\n[9]. Valcourt U, Merle B, Gineyts E, Viguet-Carrin S, Delmas PD, Garnero P. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem. 2007;282(8):5691-703.
\nhttps:\/\/doi.org\/10.1074\/jbc.M610536200
\nPMid:17142454
\n[10]. Tanaka K, Yamaguchi T, Kanazawa I, Sugimoto T. Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLOY4- A2 cells. Biochem Biophys Res Commun. 2015;461(2):193-9.
\nhttps:\/\/doi.org\/10.1016\/j.bbrc.2015.02.091
\nPMid:25721666
\n[11]. Oliaro-Bosso S, Calcio Gaudino E, Mantegna S, Giraudo E, Meda C, Viola F & Cravotto G. Regulation of HMGCoA reductase activity by policosanol and octacosadienol, a new synthetic analogue of octacosanol. Lipids 2009;44(10); 907-916.
\nhttps:\/\/doi.org\/10.1007\/s11745-009-3338-y
\nPMid:19763655
\n[12]. Horiuchi N & Maeda T. Statins and bone metabolism. Oral Disease 2006;12: 85-101.
\nhttps:\/\/doi.org\/10.1111\/j.1601-0825.2005.01172.x
\nPMid:16476028
\n[13]. Zhao J, Yue W, Zhu MJ, Sreejayan N & Du M. AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt signaling via phosphorylation of beta-catenin at Ser 552. Biochemical and Biophysical Research Communications 2010;395:146-151.
\nhttps:\/\/doi.org\/10.1016\/j.bbrc.2010.03.161
\nPMid:20361929 PMCid:PMC2864303
\n[14]. Sun-Ju Yi, Hyerim Lee, Jisu Lee, Kyubin Lee, Junil Kim, Yeojin Kim, Jae-Il Park, and Kyunghwan Kim. Bone Remodeling: Histone Modifications as Fate Determinants of Bone Cell Differentiation. Int J Mol Sci. 2019;20(13): 3147.
\nhttps:\/\/doi.org\/10.3390\/ijms20133147
\nPMid:31252653 PMCid:PMC6651527
\n[15]. Dike N. Kalu. The Rat as an Animal Model of Postmenopausal Bone Loss. In book: Sex Steroids and Bone 1994;167-181.
\nhttps:\/\/doi.org\/10.1007\/978-3-662-03043-1_9
\n[16]. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723-9.
\nhttps:\/\/doi.org\/10.2337\/db07-1472
\nPMid:18356408
\n[17]. Parhizkar S, Ibrahim R, Abdul Latiff L. Incision choice in laparatomy: a comparison of two incision techniques in ovariectomy of rats. World Appl Sci J. 2008; 4(4): 537-40.
\n[18]. Doube M, K\u0142osowski MM, Arganda-Carreras I, Cordeli\u00e8res FP, Dougherty RP, Jackson JS, et al. Free and extensible bone image analysis in Image J. Bone 2010; 47(6):1076-9.
\nhttps:\/\/doi.org\/10.1016\/j.bone.2010.08.023
\nPMid:20817052 PMCid:PMC3193171
\n[19]. Bancroft JD, Gamble M (2008) Theory and practice of histological techniques. 6th ed. Elsevier, Philadelphia: Churchill Livingstone.121-134.
\n[20]. Annemarie K.L, Elizabeth A.L, YuliyaKlymenko, YueyingLiu, OlegKim, MarwaAsem, KevinMcAbee , Matthew J.Ravosa, M. SharonStack. Methods for the visualization and analysis of extracellular matrix protein structure and degradation. Methods in Cell Biology 2018;143:79-95
\nhttps:\/\/doi.org\/10.1016\/bs.mcb.2017.08.005
\nPMid:29310793 PMCid:PMC6317720
\n[21]. Milovanovic P, Djonic D, Marshall RP, Hahn M, Nikolic S, Zivkovic V. Micro-structural basis for particular vulnerability of the superolateral neck trabecular bone in the postmenopausal women with hip fractures. Bone 2012;50 (1):63-68.
\nhttps:\/\/doi.org\/10.1016\/j.bone.2011.09.044
\nPMid:21964412
\n[22]. Thompson DD, Simmons HA, Pirie CM, Ke HZ. FDA Guidelines and animal models for osteoporosis. Bone 1995;17 (4 Suppl): 125S-133S.
\nhttps:\/\/doi.org\/10.1016\/8756-3282(95)00285-L
\n[23]. An YH; Freidman RJ (1998) Animal Models in Orthopaedic Research. Boca Raton: CRC Press. p. 284.
\n[24]. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51:1145-1149.
\nhttps:\/\/doi.org\/10.1021\/jm701272q
\nPMid:18260618
\n[25]. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 17-24.
\nhttps:\/\/doi.org\/10.2337\/dc10-0612
\nPMid:20566676 PMCid:PMC2945163
\n[26]. Bilal Osta, Giulia Benedetti, and Pierre Miossec. Classical and paradoxical effects of TNF-\u03b1 on bone homeostasis. Frontiers in Immunology 2014;5(48):1-9.
\nhttps:\/\/doi.org\/10.3389\/fimmu.2014.00048
\n[27]. Yumei Ye, Xiaoming Jia, Mandeep Bajaj,Yochai Birnbaum. Dapagliflozin Attenuates Na+\/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation. Cardiovascular Drugs and Therapy 2018;32(6):553-558.
\nhttps:\/\/doi.org\/10.1007\/s10557-018-6837-3
\nPMid:30367338
\n[28]. A.Solini, G.Sebastiani, L.Nigi, E.Santini, C.Rossi, F.Dotta. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes & Metabolism 2017;43(6): 512-520.
\nhttps:\/\/doi.org\/10.1016\/j.diabet.2017.04.002
\nPMid:28499695
\n[29]. Chang YK, Choi H, Jeong JY, Na KR, Lee KW, Lim BJ, Choi DE. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury. PLoS One 2016; 11(7):e0158810.
\nhttps:\/\/doi.org\/10.1371\/journal.pone.0158810
\nPMid:27391020 PMCid:PMC4938401
\n[30]. Yao D1, Wang S, Wang M, Lu W. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1 receptor for advanced glycation end products nuclear factor \u03baB signaling pathway. Mol Med Rep. 2018; 18(4):3625-3630.
\nhttps:\/\/doi.org\/10.3892\/mmr.2018.9393
\n[31]. Naoto Terami, Daisuke Ogawa , Hiromi Tachibana, Takashi Hatanaka, Jun Wada, Atsuko Nakatsuka, Jun Eguchi, Chikage Sato Horiguchi, Naoko Nishii, Hiroshi Yamada, Kohji Takei, and Hirofumi Makino. Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db\/db Mice. PLoS One 2014;9(6): e100777.
\nhttps:\/\/doi.org\/10.1371\/journal.pone.0100777
\nPMid:24960177 PMCid:PMC4069074
\n[32]. Ali F, Abdel-Wahabab, Ghazi A.Bamagousa, Randa M.Al-Harizy , Naser A.ElSawy, Naiyer Shahzad , Ibrahim A.Ibrahim, Saeed S. AlGhamdi. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. Biomedicine & Pharmacotherapy 2018;103:59-66.
\nhttps:\/\/doi.org\/10.1016\/j.biopha.2018.03.176
\nPMid:29635129
\n[33]. Ying-Ying Chen, Tsung-Tien Wu, Chiu-Yi Ho, Tung-Chen Yeh, Gwo-Ching Sun, Ya-Hsin Kung, Tzyy-Yue Wong, Ching-Jiunn Tseng, and Pei-Wen Cheng. Dapagliflozin Prevents NOX- and SGLT2-Dependent Oxidative Stress in Lens Cells Exposed to Fructose-Induced Diabetes Mellitus. Int J Mol Sci. 2019;20(18): 4357.
\nhttps:\/\/doi.org\/10.3390\/ijms20184357
\nPMid:31491943 PMCid:PMC6770809
\n[34]. Bolinder J, Ljunggren \u00d6, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16(2):159-69.
\nhttps:\/\/doi.org\/10.1111\/dom.12189
\nPMid:23906445
\n[35]. Ljunggren \u00d6, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14(11):990-9.
\nhttps:\/\/doi.org\/10.1111\/j.1463-1326.2012.01630.x
\nPMid:22651373
\n[36]. Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
\nhttps:\/\/doi.org\/10.2337\/dc11-0606
\nPMid:21816980 PMCid:PMC3161265
\n[37]. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-657.
\nhttps:\/\/doi.org\/10.2337\/dc08-1863
\nPMid:19114612 PMCid:PMC2660449
\n[38]. De Jong MA, Petrykiv SI, Laverman GD, et al. Effects of dapagliflozin on circulating markers of phosphate homeostasis. Clin J Am Soc Nephrol. 2019;14:66-73.
\nhttps:\/\/doi.org\/10.2215\/CJN.04530418
\nPMid:30559106 PMCid:PMC6364523
\n[39]. Hafiza A. Sharaf, Nermeen M. Shaffi , Fatma A. Morsy, Manal A. Badawi, Naglaa F. Abbas. Role of some phytoestrogens in recovering bone loss: histological results from experimental ovariectomized rat models. Journal of the Arab Society for Medical Research 2015;10:65-75.
\nhttps:\/\/doi.org\/10.4103\/1687-4293.175880
\n[40]. Smith R, Wordsworth P. Osteoporosis. Clinical and Biochemical disorders of the skeleton 2005;123.
\n[41]. Ji-Yu Wang, Yan-Zhen Cheng, Shuang-Li Yang, Min An, Hua Zhang, Hong Chen and Li Yang. Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria. Frontiers in Endocrinology 2019;10:1-14.
\nhttps:\/\/doi.org\/10.3389\/fendo.2019.00700
\nPMid:31781028 PMCid:PMC6856656
\n[42]. Kohan D, Fioretto P, Tang W. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;4:962-971.
\nhttps:\/\/doi.org\/10.1038\/ki.2013.356
\nPMid:24067431 PMCid:PMC3973038<\/p>\n

\n\t\t\t

\n \t Cite this article:<\/strong><\/span> Amany Ali Nawar, Nancy Mohamed El Sekily. PROMISING EFFECT OF DAPAGLIFLOZIN ON OVARIECTOMIZED RAT MODEL OF OSTEOPOROSIS. Int J Anat Res 2020;8(3.3):7728-7737.\u00a0DOI:\u00a0<\/strong>10.16965\/ijar.2020.204\u00a0 \n <\/div>\t\n\t\t\n","protected":false},"excerpt":{"rendered":"

Type of Article:\u00a0\u00a0Original Research Volume 8; Issue 3.3 (September 2020) Page No.:\u00a07728-7737 DOI:\u00a0https:\/\/dx.doi.org\/10.16965\/ijar.2020.204 PROMISING EFFECT OF DAPAGLIFLOZIN ON OVARIECTOMIZED RAT MODEL OF OSTEOPOROSIS Amany Ali Nawar 1, Nancy Mohamed El Sekily *2. 1 Clinical pharmacology Department, Faculty of Medicine, Alexandria University, Egypt. *2 Anatomy and Embryology Department, Faculty of Medicine, Alexandria University, Egypt. Corresponding author:
+ Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.ijmhr.org\/IntJAnatRes\/wp-json\/wp\/v2\/pages\/2363"}],"collection":[{"href":"https:\/\/www.ijmhr.org\/IntJAnatRes\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ijmhr.org\/IntJAnatRes\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ijmhr.org\/IntJAnatRes\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ijmhr.org\/IntJAnatRes\/wp-json\/wp\/v2\/comments?post=2363"}],"version-history":[{"count":1,"href":"https:\/\/www.ijmhr.org\/IntJAnatRes\/wp-json\/wp\/v2\/pages\/2363\/revisions"}],"predecessor-version":[{"id":2370,"href":"https:\/\/www.ijmhr.org\/IntJAnatRes\/wp-json\/wp\/v2\/pages\/2363\/revisions\/2370"}],"wp:attachment":[{"href":"https:\/\/www.ijmhr.org\/IntJAnatRes\/wp-json\/wp\/v2\/media?parent=2363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}